PDCD1 and classic Hodgkin lymphoma: In a phase II trial enrolling 61 R/R cHL patients, those who received the anti-PD-1 camrelizumab plus decitabine had higher rates of CR and better PFS in respect of those who received camrelizumab alone (CR 79% vs. 32%; median PFS 35 months vs. 15.5 months, respectively) [132].